Current state of ERG as biomarker in prostatic adenocarcinoma

Balazs Acs, Tibor Szarvas, Nora Szekely, Peter Nyirady, A. Marcell Szasz

Research output: Contribution to journalArticle

2 Citations (Scopus)


In this review we briefly discuss the possible biomarkers of prostate cancer among them we focus and analyze the relevance of TMPRSS2-ERG fusion gene in line with ERG expression in the diagnosis of prostate cancer. Starting at diagnosis and genetic alterations in prostate carcinomas, we examine the incidence and detection of the most common genetic aberration in this tumor and its protein product as well. We also examined the correlation of clinicopathological factors and prognosis with ERG and the TMPRSS2-ERG fusion oncogene and ERG expression as predictive markers.

Original languageEnglish
Pages (from-to)643-651
Number of pages9
JournalCurrent cancer drug targets
Issue number8
Publication statusPublished - Oct 1 2015


  • Diagnosis
  • ERG
  • Prediction
  • Prognosis
  • Prostate carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Fingerprint Dive into the research topics of 'Current state of ERG as biomarker in prostatic adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this